On Monday, FibroGen Inc (NASDAQ: FGEN) was -2.34% drop from the session before settling in for the closing price of $0.33. A 52-week range for FGEN has been $0.18 – $2.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -2.51% over the past five years. When this article was written, the company’s average yearly earnings per share was at 69.86%. With a float of $93.81 million, this company’s outstanding shares have now reached $100.77 million.
Let’s look at the performance matrix of the company that is accounted for 486 employees. In terms of profitability, gross margin is 76.87%, operating margin of -62.75%, and the pretax margin is -69.56%.
FibroGen Inc (FGEN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward FibroGen Inc stocks. The insider ownership of FibroGen Inc is 6.91%, while institutional ownership is 45.77%. The most recent insider transaction that took place on Jun 12 ’24, was worth 25,884. In this transaction Chief Medical Officer of this company bought 22,123 shares at a rate of $1.17, taking the stock ownership to the 82,123 shares. Before that another transaction happened on Mar 07 ’24, when Company’s CEO bought 50,000 for $1.91, making the entire transaction worth $95,470. This insider now owns 470,178 shares in total.
FibroGen Inc (FGEN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.86% per share during the next fiscal year.
FibroGen Inc (NASDAQ: FGEN) Trading Performance Indicators
You can see what FibroGen Inc (FGEN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of FibroGen Inc (FGEN)
FibroGen Inc (NASDAQ: FGEN) saw its 5-day average volume 0.7 million, a negative change from its year-to-date volume of 2.12 million. As of the previous 9 days, the stock’s Stochastic %D was 18.42%. Additionally, its Average True Range was 0.04.
During the past 100 days, FibroGen Inc’s (FGEN) raw stochastic average was set at 12.73%, which indicates a significant increase from 11.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.58% in the past 14 days, which was lower than the 137.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3517, while its 200-day Moving Average is $0.8834. Nevertheless, the first resistance level for the watch stands at $0.3464 in the near term. At $0.3677, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3854. If the price goes on to break the first support level at $0.3074, it is likely to go to the next support level at $0.2897. Assuming the price breaks the second support level, the third support level stands at $0.2684.
FibroGen Inc (NASDAQ: FGEN) Key Stats
There are 100,770K outstanding shares of the company, which has a market capitalization of 32.76 million. As of now, sales total 147,750 K while income totals -284,230 K. Its latest quarter income was 46,330 K while its last quarter net income were -17,080 K.
